Scholarlink

<p>We investigate the clinical significance of the peroxiredoxin (PRDX) family in multiple myeloma (MM) patients, focusing on its diagnostic and prognostic value, biological role and impact on the immune system. Using bioinformatics tools, such as CCLE, GEO, TCGA-MMRF, Kaplan–Meier plotter, enrichment and CIBERSORT analyses, we systematically characterized the expression levels, impact on survival and biological significance of PRDXs in MM. Bone marrow aspiration and clinical data were subsequently collected from MM patients to validate the findings related to PRDX2 from the databases. Finally, PRDX2 silencing in vitro modulated cell proliferation, immune infiltration and ferroptosis susceptibility. Compared with those in normal plasma cells, the expression levels of PRDX2/4/5/6 were significantly increased in myeloma cells. Furthermore, in relapsed MM cells, PRDX1/2/3/6 expression was significantly upregulated compared with that at baseline. Notably, PRDX2 was found to be highly expressed and associated with poor tumor characteristics, potentially contributing to disease progression and correlating with unfavourable prognosis. PRDX-related genes participate in various biological functions, influence metabolic pathways and may regulate ferroptosis and immune-related pathways in myeloma cells. This study is the first comprehensive analysis of the potential diagnostic and prognostic impact of the PRDXs family in MM, highlighting their significant associations with ferroptosis and the immune microenvironment. These findings provide a strong experimental and theoretical foundation for developing novel therapeutic strategies targeting ferroptosis and immunotherapy in MM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月25日

查看全文
  • Yue Chen,
  • Xiaohuan Peng,
  • Zuxi Feng,
  • Li Zhang,
  • Jun Bai,
  • Yanhong Li,
  • Lijuan Li,
  • Liansheng Zhang

摘要

We investigate the clinical significance of the peroxiredoxin (PRDX) family in multiple myeloma (MM) patients, focusing on its diagnostic and prognostic value, biological role and impact on the immune system. Using bioinformatics tools, such as CCLE, GEO, TCGA-MMRF, Kaplan–Meier plotter, enrichment and CIBERSORT analyses, we systematically characterized the expression levels, impact on survival and biological significance of PRDXs in MM. Bone marrow aspiration and clinical data were subsequently collected from MM patients to validate the findings related to PRDX2 from the databases. Finally, PRDX2 silencing in vitro modulated cell proliferation, immune infiltration and ferroptosis susceptibility. Compared with those in normal plasma cells, the expression levels of PRDX2/4/5/6 were significantly increased in myeloma cells. Furthermore, in relapsed MM cells, PRDX1/2/3/6 expression was significantly upregulated compared with that at baseline. Notably, PRDX2 was found to be highly expressed and associated with poor tumor characteristics, potentially contributing to disease progression and correlating with unfavourable prognosis. PRDX-related genes participate in various biological functions, influence metabolic pathways and may regulate ferroptosis and immune-related pathways in myeloma cells. This study is the first comprehensive analysis of the potential diagnostic and prognostic impact of the PRDXs family in MM, highlighting their significant associations with ferroptosis and the immune microenvironment. These findings provide a strong experimental and theoretical foundation for developing novel therapeutic strategies targeting ferroptosis and immunotherapy in MM.